SynCore Biotechnology Co.,Ltd (TPEX:4192)
Taiwan · Delayed Price · Currency is TWD 24.00
-0.40 (-1.64%)
Jan 22, 2026, 1:10 PM CST
TPEX:4192 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 26.26 | 23.34 | 20.2 | 15.86 | 6.94 | 13.34 | Upgrade | |
Revenue Growth (YoY) | 14.51% | 15.55% | 27.36% | 128.52% | -47.97% | 2.85% | Upgrade |
Cost of Revenue | 7.17 | 10.45 | 19.68 | 6.77 | 3.97 | 7.15 | Upgrade |
Gross Profit | 19.09 | 12.89 | 0.52 | 9.09 | 2.97 | 6.19 | Upgrade |
Selling, General & Admin | 43.32 | 42.33 | 42.09 | 43.33 | 38.62 | 38.62 | Upgrade |
Research & Development | 24.71 | 28.31 | 3.94 | 157.23 | 422.97 | 363.21 | Upgrade |
Operating Expenses | 68.03 | 70.64 | 46.02 | 200.56 | 461.59 | 401.84 | Upgrade |
Operating Income | -48.95 | -57.76 | -45.5 | -191.47 | -458.62 | -395.65 | Upgrade |
Interest Expense | -0.22 | -0.3 | -0.78 | -2.27 | -2.04 | -3.39 | Upgrade |
Interest & Investment Income | 2.22 | 2.31 | 2.37 | 1.42 | 1.03 | 1.24 | Upgrade |
Currency Exchange Gain (Loss) | 0.16 | 1.16 | 5.65 | -2.99 | -4.17 | -9.75 | Upgrade |
Other Non Operating Income (Expenses) | 0 | 0.01 | 0.09 | 6.77 | 5.2 | 8.24 | Upgrade |
EBT Excluding Unusual Items | -46.79 | -54.58 | -38.18 | -188.54 | -458.6 | -399.31 | Upgrade |
Gain (Loss) on Sale of Investments | 0.38 | 0.3 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | -0.13 | - | 0.39 | Upgrade |
Other Unusual Items | - | - | 0.01 | - | - | - | Upgrade |
Pretax Income | -46.41 | -54.28 | -38.17 | -188.67 | -458.6 | -398.92 | Upgrade |
Net Income | -46.41 | -54.28 | -38.17 | -188.67 | -458.6 | -398.92 | Upgrade |
Net Income to Common | -46.41 | -54.28 | -38.17 | -188.67 | -458.6 | -398.92 | Upgrade |
Shares Outstanding (Basic) | 35 | 35 | 32 | 31 | 30 | 28 | Upgrade |
Shares Outstanding (Diluted) | 35 | 35 | 32 | 31 | 30 | 28 | Upgrade |
Shares Change (YoY) | -0.59% | 9.69% | 4.27% | 1.26% | 9.16% | 15.56% | Upgrade |
EPS (Basic) | -1.32 | -1.54 | -1.19 | -6.14 | -15.10 | -14.34 | Upgrade |
EPS (Diluted) | -1.32 | -1.54 | -1.19 | -6.14 | -15.10 | -14.34 | Upgrade |
Free Cash Flow | -30 | -49.45 | -82.79 | -209.75 | -230.15 | -321.76 | Upgrade |
Free Cash Flow Per Share | -0.85 | -1.41 | -2.58 | -6.82 | -7.58 | -11.57 | Upgrade |
Gross Margin | 72.69% | 55.22% | 2.58% | 57.30% | 42.79% | 46.42% | Upgrade |
Operating Margin | -186.42% | -247.49% | -225.30% | -1207.50% | -6609.30% | -2966.74% | Upgrade |
Profit Margin | -176.76% | -232.60% | -189.01% | -1189.80% | -6608.98% | -2991.29% | Upgrade |
Free Cash Flow Margin | -114.27% | -211.89% | -409.92% | -1322.74% | -3316.73% | -2412.70% | Upgrade |
EBITDA | -41 | -49.5 | -36.99 | -165.71 | -454.51 | -388.74 | Upgrade |
EBITDA Margin | -156.16% | -212.10% | -183.16% | - | - | - | Upgrade |
D&A For EBITDA | 7.95 | 8.26 | 8.51 | 25.77 | 4.11 | 6.91 | Upgrade |
EBIT | -48.95 | -57.76 | -45.5 | -191.47 | -458.62 | -395.65 | Upgrade |
EBIT Margin | -186.42% | -247.49% | -225.30% | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.